Reproductive Medicine Center, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan, People's Republic of China.
Reprod Health. 2020 Nov 20;17(1):181. doi: 10.1186/s12978-020-01042-2.
Letrozole can significantly decrease the estrogen level, and has been administrated to prevent the incidence of early ovary hyperstimulation syndrome (OHSS). However, the effect of Letrozole on prevention of OHSS reached to controversial conclusions. The present meta-analysis aim to examine whether Letrozole could reduce the incidence of early OHSS after assisted reproductive technology (ART).
An exhaustive electronic literature search was conducted on MEDLINE, Google Scholar, CNKI and WANFANG MED ONLINE, from inception until May 2018. We include clinical trials that examined the effect of Letrozole on the prevention of early OHSS. The main outcome measures were the incidence of total early OHSS, mild early OHSS, moderate early OHSS, and severe early OHSS.
Eight studies included in the review. Of these, five publications evaluated the effect of Letrozolel on the prevention of total, mild, moderate, and severe OHSS, respectively. The results indicated that there was a significantly decreased incidence of total OHSS with Letrozole compared with control group, and there were no significantly differences in the incidence of mild, moderate, and severe OHSS between study group with Letrozole and control group. Eight studies reported the incidence of moderate + severe OHSS. We found a significant decrease in incidence of moderate + severe OHSS in high-risk women with Letrozole.
Letrozole has no beneficial effect on the prevention of mild, moderate, and severe OHSS, individually; Letrozole should not be considered as the first-line treatment for prevention of OHSS. Further cohort studies are required to explore the effect of Letrozole on the prevention of OHSS. This study aimed to examine whether Letrozole could reduce the incidence of early OHSS after assisted reproductive technology (ART). A meta-analysis including 8 studies was conducted. There were no significantly differences in the incidence of mild, moderate, and severe OHSS between study group with Letrozole and control group. Letrozole has no beneficial effect on the prevention of mild, moderate, and severe OHSS, individually.
来曲唑可显著降低雌激素水平，已被用于预防早发性卵巢过度刺激综合征（OHSS）。然而，来曲唑预防 OHSS 的效果存在争议。本荟萃分析旨在研究来曲唑是否能降低辅助生殖技术（ART）后早发性 OHSS 的发生率。
系统检索 MEDLINE、Google Scholar、中国知网（CNKI）和万方数据库（WANFANG MED ONLINE），检索时限均从建库至 2018 年 5 月。纳入来曲唑预防早发性 OHSS 的临床试验。主要结局指标为总早发性 OHSS、轻度早发性 OHSS、中度早发性 OHSS 和重度早发性 OHSS 的发生率。
共纳入 8 项研究。其中，5 项研究分别评估了来曲唑预防总、轻、中、重度 OHSS 的效果。结果显示，与对照组相比，来曲唑组总早发性 OHSS 的发生率显著降低，而两组间轻度、中度和重度 OHSS 的发生率无显著差异。8 项研究报告了中重度 OHSS 的发生率。我们发现，在高危女性中，来曲唑可显著降低中重度 OHSS 的发生率。
来曲唑对预防轻、中、重度 OHSS 无明显作用，不应作为预防 OHSS 的一线治疗方法。需要进一步的队列研究来探讨来曲唑预防 OHSS 的效果。本研究旨在研究来曲唑是否能降低辅助生殖技术（ART）后早发性卵巢过度刺激综合征（OHSS）的发生率。对 8 项研究进行荟萃分析。来曲唑组和对照组之间在轻度、中度和重度 OHSS 的发生率方面无显著差异。来曲唑对预防轻、中、重度 OHSS 均无明显作用。
